Xenoport (f/k/a XNPT)

[stocktrademan]

$XNPT recent news/filings

bullish 6.35
descending channel breakout


## source: finance.yahoo.com

Wed, 25 Nov 2015 13:57:00 GMT ~ Be On Top Of The Latest Developments - Research on MarineMax, World Acceptance, Xenoport and Stone Energy

[Accesswire] - NEW YORK, NY / ACCESSWIRE / November 25, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: MarineMax ...

read full: http://finance.yahoo.com/news/top-latest-developments-research-marinemax-135700826.html
*********************************************************

Tue, 17 Nov 2015 13:15:00 GMT ~ What does the Technical Data Say - Research on United Insurance, MarineMax, World Acceptance and Xenoport

[Accesswire] - NEW YORK, NY / ACCESSWIRE / November 17, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: United Insurance ...

read full: http://finance.yahoo.com/news/does-technical-data-research-united-131500593.html
*********************************************************

Fri, 13 Nov 2015 18:04:31 GMT ~ XENOPORT INC Financials


read full: http://finance.yahoo.com/q/is?s=xnpt
*********************************************************

Tue, 10 Nov 2015 13:20:00 GMT ~ The Price Data Tells the Story - Research on World Acceptance, Xenoport, Stone Energy and Boot Barn Holdings

[Accesswire] - NEW YORK, NY / ACCESSWIRE / November 10, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: World Acceptance ...

read full: http://finance.yahoo.com/news/price-data-tells-story-research-132000317.html
*********************************************************

Thu, 05 Nov 2015 22:46:56 GMT ~ XENOPORT INC Files SEC form 10-Q, Quarterly Report


read full: http://biz.yahoo.com/e/151105/xnpt10-q.html
*********************************************************

$XNPT charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$XNPT company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/XNPT/company-info
Ticker: $XNPT
OTC Market Place: Not Available
CIK code: 0001130591
Company name: XenoPort, Inc.
Incorporated In: DE, USA

$XNPT share structure

## source: otcmarkets.com

Market Value: $406,424,077 a/o Nov 24, 2015
Shares Outstanding: 63,207,477 a/o Oct 15, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001

$XNPT extra dd links

Company name: XenoPort, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/XNPT/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/XNPT/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=XNPT+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=XNPT+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=XNPT+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/XNPT/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/XNPT/news - http://finance.yahoo.com/q/h?s=XNPT+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/XNPT/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/XNPT/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/XNPT/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/XNPT/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/XNPT/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/XNPT/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/XNPT/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/XNPT/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=XNPT+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/XNPT
DTCC (dtcc.com): http://search2.dtcc.com/?q=XenoPort%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=XenoPort%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=XenoPort%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/XNPT/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/XNPT
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/XNPT/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/XNPT/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/XNPT/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001130591&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/XNPT/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/XNPT/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/XNPT/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/XNPT/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=XNPT&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=XNPT
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/XNPT/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=XNPT+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=XNPT+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=XNPT
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=XNPT
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=XNPT+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/XNPT/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=XNPT+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/XNPT.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=XNPT
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/XNPT/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/XNPT/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/XNPT/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/XNPT/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/XNPT
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/XNPT
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/XNPT:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=XNPT
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=XNPT



$XNPT DD Notes ~ http://www.ddnotesmaker.com/XNPT

[PAC]

XNPT 5.4 short ready

[Warchest]

exit now out sell trigger 2 min away

[Warchest]

CASH N CARRY !!!!!!

[Warchest]

moon boots !!! $$$$$

[Warchest]

oh yes we did ~~~~

[Warchest]

can we crack hod ~~ $5.09

[Warchest]

we are in a buy trigger !! pressure

[Warchest]

.51

[Warchest]

squeeze there azzes we want more

[Warchest]

snipers attack

[Warchest]

.44 !!!

[Warchest]

lets squeeze them

[Warchest]

$5.00 come give it to me

[Warchest]

lets crack $5.00 should we !!!

[Warchest]

.37 cents $$$$

[Warchest]

.23 cents green so far !!!! more coming $$$$

[Warchest]

lets crack that hod ~

[Warchest]

voom voom ~

[ClayTrader]

* * $XNPT Video Chart 10-02-15 * *

Link to Video - click here to watch the technical chart video

[Motba]

BOOM!!!! Take profits baby!!!

[e2daD]

WHATS GOING ON HERE>!???!??

[Lama]

The shorts were involved yesterday...FINRA suggests 2.5 million shorted..Would speculate a rebound...depending on the short interest.

[Bob Stocks]

Also, the AE

[Bob Stocks]

Did you look closely at the results? The mean PASI score was lower than the placebo....but it is still considered positive....In conclusion, even the company doesn't even know if it works

[ClayTrader]

* * $XNPT Video Chart 09-15-15 * *

Link to Video - click here to watch the technical chart video

[TheFinalCD]

$5.04 LOW SO FAR

WHERES THE BOTTOM?

[henrytrean]

What wrong with this stock ??

[TheFinalCD]

5.20'S WHAT A DEBACLE


XNPT

[TheFinalCD]

FROM $8 ON GOOD BEWS TO UNDER $6= http://www.streetinsider.com/Equity+Offerings/XenoPort+(XNPT)+Files+$150M+Common+Stock,+Warrants+Shelf/10796506.html


WHAT A DAM SHAME!!!!!

[Stockexpertpro]

Cashless Warrants YUCK Another GBSN FREE AEZS

XenoPort (XNPT) Files $150M Common Stock, Warrants Shelf

http://www.streetinsider.com/Equity+Offerings/XenoPort+(XNPT)+Files+$150M+Common+Stock,+Warrants+Shelf/10796506.html

XenoPort (NASDAQ: XNPT) filed a registration with the U.S. SEC to sell up to $150 million worth of common stock, warrants, or a combination of the two.

[crudeoil24]

XNPT XenoPort's stock surges after psoriasis treatment meets trial's primary endpoint
16 minutes ago - DJNF

XenoPort Inc.'s stock (XNPT) surged 9.5% in premarket trade Tuesday, after the company announced positive results from a Phase 2 trial of its treatment for psoriasis. The company said its treatment, known as XP23829, met its primary endpoints in the trial for both 800 milligram once daily and 400 milligram twice daily doses. "We believe these clinical data demonstrate for the first time that a [monomethyl fumarate] prodrug other than dimethyl fumarate (DMF) can be effective in reducing lesions in psoriatic patients," said XenoPort Chief Medical Officer Richard Kim. The company said TXP23829 was also safe and generally well tolerated. The stock has gained 5.2% over the past three months through Monday, while the S&P 500 has lost 6.3%.
-Tomi Kilgore; 415-439-6400; [e-mail]



(END) Dow Jones Newswires

September 15, 2015 07:51 ET (11:51 GMT)

[stocktrademan]

$XNPT DD Notes ~ http://www.ddnotesmaker.com/XNPT

bullish
good price action
higher highs and higher lows


$XNPT recent news/filings

## source: finance.yahoo.com

Tue, 18 Nov 2014 11:17:52 GMT ~ Surging Earnings Estimates Signal Good News for Xenoport (XNPT)


read full: http://finance.yahoo.com/news/surging-earnings-estimates-signal-good-111752956.html
*********************************************************

Fri, 14 Nov 2014 18:04:43 GMT ~ XENOPORT INC Financials


read full: http://finance.yahoo.com/q/is?s=xnpt
*********************************************************

Tue, 11 Nov 2014 11:35:19 GMT ~ Can the Uptrend Continue for XenoPort (XNPT)?


read full: http://finance.yahoo.com/news/uptrend-continue-xenoport-xnpt-113519996.html
*********************************************************

Sat, 08 Nov 2014 00:08:37 GMT ~ 10-Q for XenoPort, Inc.


read full: http://www.companyspotlight.com/routers/headline/19017/10004/6410148?cp_code=YAH1&1415405317
*********************************************************

Thu, 06 Nov 2014 18:43:13 GMT ~ XenoPort to Present at the Credit Suisse Healthcare Conference

[at noodls] - SANTA CLARA, Calif.--(BUSINESS WIRE)-- XenoPort, Inc. (Nasdaq:XNPT) announced today that it will provide access via the World Wide Web to its presentation at the 2014 Credit Suisse Healthcare Conference ...

read full: http://www.noodls.com/view/F882B4FE2EC71B5B6D7B65F7818B057B979F76EC
*********************************************************


$XNPT charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$XNPT company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/XNPT/company-info
Ticker: $XNPT
OTC Market Place: Not Available
CIK code: 0001130591
Company name: XenoPort, Inc.
Incorporated In: DE, USA


$XNPT share structure

## source: otcmarkets.com

Market Value: $535,245,329 a/o Nov 25, 2014
Shares Outstanding: 62,237,829 a/o Oct 15, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001
$XNPT extra dd links

Company name: XenoPort, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/XNPT/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/XNPT/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=XNPT+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=XNPT+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=XNPT+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/XNPT/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/XNPT/news - http://finance.yahoo.com/q/h?s=XNPT+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/XNPT/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/XNPT/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/XNPT/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/XNPT/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/XNPT/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/XNPT/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/XNPT/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/XNPT/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=XNPT+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/XNPT
DTCC (dtcc.com): http://search2.dtcc.com/?q=XenoPort%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=XenoPort%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=XenoPort%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/XNPT/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/XNPT
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/XNPT/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/XNPT/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/XNPT/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001130591&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/XNPT/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/XNPT/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/XNPT/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/XNPT/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=XNPT&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=XNPT
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/XNPT/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=XNPT+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=XNPT+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=XNPT
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=XNPT
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=XNPT+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/XNPT/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=XNPT+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/XNPT.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=XNPT
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/XNPT/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/XNPT/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/XNPT/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/XNPT/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/XNPT
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/XNPT
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/XNPT:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=XNPT
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=XNPT



$XNPT DD Notes ~ http://www.ddnotesmaker.com/XNPT

[afxm]

NASDAQ site has institutional ownership @ 90%

[oldberkeley]

Can't reply on other board, so doing so here:

The reply about your stop order not executing in a fast-moving market is incorrect.

Once the stop order amount is reached, it automatically is changed to a market order. Like all market orders, it will be executed at the best possible price.

Granted, in a fast-moving market this may be below your original stop order amount, but it will be executed.

Don't get discouraged, many very experienced biotech traders got killed on that one (some are admitting it, some are lying), keep fighting and you'll get it back.

[maytepper]

Cowen Maintains Market Perform On XenoPort Following 2Q14 Results http://www.smarteranalyst.com/2014/08/07/cowen-maintains-market-perform-on-xenoport-following-2q14-results/

[surf1944]

1:40AM Xenoport provides update on XP23829 development and HORIZANT performance highlights (XNPT) 6.59 : Co provides an update on XP23289 development, including feedback from the FDA on the potential development plans, and XenoPort's progress on commercializing HORIZANT Extended-Release Tablets.

XenoPort reported that it received feedback from the FDA Division of Neurology Products regarding potential development plans for XP23829 as a potential treatment for patients with relapsing forms of multiple sclerosis.
Based on the feedback, XenoPort believes that the FDA would allow it to initiate potential Phase 3 clinical development using XP23829 doses that produce monomethyl fumarate exposure similar to that produced by the approved dose of TECFIDERA. The FDA encouraged the exploration of multiple doses of XP23829 to assess the potential advantages of doses that produced either higher or lower MMF exposure.
The FDA also provided responses to the company's questions about its proposed development strategies to support the potential submission of a New Drug Application to the FDA under Section 505(b)(2).
XenoPort believes that the FDA will require additional information on XP23829 before determining the applicability of the Section 505(b)(2) pathway. XenoPort will continue discussions with the FDA regarding what information could potentially be referenced in a Section 505(b)(2) NDA.
XenoPort also indicated that its plans for 2014 include the submission of an Investigational New Drug application to the FDA Division of Dermatology for XP23829 as a potential treatment for moderate-to-severe plaque psoriasis. XenoPort plans to initiate a Phase 2 clinical trial of XP23829 in patients with moderate-to-severe plaque psoriasis by mid-2014.

HORIZANT update
XenoPort also reported its progress in the commercialization of HORIZANT since it began its promotional efforts on June 1, 2013. XenoPort's efforts are focused on physician specialists and patients within 40 U.S. geographic territories. Based on a variety of metrics, XenoPort believes it has made substantial progress in enhancing the value of the HORIZANT business.

[surf1944]

2:27AM Xenoport issues statement regarding letter from Clinton Group (XNPT) 6.02 : Co issued the following statement:

"The XenoPort Board of Directors has received the letter sent today from the Clinton Group. The XenoPort Board and management team appreciate stockholder input regarding the company, and we will continue to review all aspects of the company's business. We remain focused on enhancing stockholder value and welcome stockholder input regarding this objective."

[surf1944]

8:30AM Xenoport announces inclusion of HORIZANT (gabapentin enacarbil) in the WED Foundation Revised Consensus Statement on the Management of RLS/WED (XNPT) 5.89 : Co announced the inclusion of gabapentin enacarbil, the active ingredient in HORIZANT (gabapentin enacarbil) Extended-Release Tablets, as an initial therapy for chronic persistent restless legs syndrome/Willis-Ekbom disease (RLS/WED) in an updated treatment algorithm for patients with RLS/WED. The WED Foundation's algorithm, published in the current issue of Mayo Clinic Proceedings, provides information for physicians determining treatment choices for RLS/WED based on disease severity, existing comorbidities and the long-term benefits and risks of each major class of medications.

The algorithm, first published in 2004, was updated to accommodate several changes in the RLS/WED treatment landscape, including additional knowledge of treatment with nonergot dopamine agonists, increased experience with calcium channel alpha-2-delta ligands and the fact that several long-acting drugs have become available. According to the revised algorithm, either non-ergot dopamine agonists or the calcium channel alpha-2-delta ligands are recommended as initial treatment for patients with chronic persistent RLS/WED, and the choice of the initial treatment should be based on the individual clinical features of RLS/WED in a given patient.

[Penny Roger$]

$XNPT ~ Daily Par Sar Buy Signal ~ Criteria alert triggered during a recent trading session!

$XNPT has just triggered the "Parabolic SAR Buy Signals" scan criteria at Stockcharts.com
~ http://tinyurl.com/SAR-BUY ~







For a more in Depth study and DD profile, similar to the one contained in this link: ~ http://tinyurl.com/DDexample ~
Click the following link and type ticker or brief message asking me about the DD: ~ http://tinyurl.com/GET-THE-DD ~

What does the scan "Parabolic SAR Buy Signals" mean? Below is an image example and study link.
~ http://stockcharts.com/school/doku.php?id=chart_school:technical_indicators:parabolic_sar ~


To find other similar posts of "XNPT" utilize the links that follow.
Search MACDgyver's "Parabolic SAR Buy Signals" posts: ~ http://investorshub.advfn.com/boards/msgsearchbymember.aspx?searchID=251916&srchyr=2013&SearchStr=ParSarBuyScan ~
Search MACDgyver's posts for symbol "XNPT": ~ http://investorshub.advfn.com/boards/msgsearchbymember.aspx?searchID=251916&srchyr=2013&SearchStr=XNPT ~
Search Ihub for "XNPT" posts: ~ http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=XNPT ~


For more in depth training and information visit Chartschool on the Stockcharts page.
~ http://stockcharts.com/school/doku.php?id=chart_school ~


Also don't forget the Ihub Edu Channel.
~ http://investorshub.advfn.com/boards/education.aspx ~


c

[reddymade]

Price target lowered from $16 to $6 by Wedbush:
Wedbush downgraded XenoPort and lowered its price target for shares to $6 from $16 after Arbaclofen Placarbil failed in a Phase III trial for multiple sclerosis spasticity.

[surf1944]

8:47AM On The Wires (WIRES) :XenoPort (XNPT) announced that shipments of Horizant (gabapentin enacarbil) Extended-Release Tablets to its distributor in the U.S. have commenced. Depending on individual pharmacy ordering patterns, the product is anticipated to be generally available to patients in the first week of June.

[surf1944]

6:31AM Xenoport provides update on its introduction of Horizant; co is hopeful that new inventory of Horizant will be available in pharmacies in June (XNPT) 7.26 : Co reported that GlaxoSmithKline (GSK), who holds commercialization rights to Horizant (gabapentin enacarbil) Extended-Release Tablets in the United States during a transition period ending on April 30, 2013, has experienced manufacturing delays that have resulted in a stockout of Horizant. GSK continues to have sole responsibility for the manufacture and supply of Horizant during this transition period and is working to resolve the manufacturing issues with its contract manufacturer. Although the timing is not yet certain, XenoPort is hopeful that new inventory of Horizant will be available in pharmacies in June.

[onkelhubert]

sold it today @$7.01. wasn't satisfied with the trading lately.

[onkelhubert]

bought the volume today. 1k shares @$7.20.

[surf1944]

http://investor.xenoport.com/releases.cfm

[kooleraid]

Break of $7.50 i believe does wonders for the stock. Coming week is a low volume week that really moves what it favors. Good stock for this week to watch. (imo) Took a starter Friday and will add Monday accordingly. See the latest developments that will have positive effect on the pps.

XNPT $7.46: 11/8 GSK is purchasing $20M worth of XNPT stock ~1.84M shares at $10.863 a piece ~46% premium to Wednesday close. XNPT also has the option to require GSK to purchase up to additional $20M at 12.5% premium to avg of 10-trading day closing price prior to the day XNPT notifies GSK of its decision to exercise this option.

XNPT $7.46: 11/28 XNPT to present at 24th annual Piper Jaffray Health Care Conference

[surf1944]

6:31AM Xenoport and GlaxoSmithKline (GSK) mutually agree to terminate their collaboration on Horizant; Xenoport reacquires rights to Horizant in the U.S. (XNPT) 7.46 : Co announced that it has reached an agreement with Glaxo Group (GSK) to terminate their collaboration agreement concerning Horizant (gabapentin enacarbil) Extended-Release Tablets, for which GSK held commercialization rights and certain development rights in the U.S.. Pursuant to a termination and transition agreement entered into between the parties, GSK is returning Horizant rights to XenoPort and providing certain assistance during a transition period. The termination and transition agreement also provides for a mutual release of claims and resolves all ongoing litigation between the parties. During the transition period that will end on April 30, 2013, GSK will continue to exclusively commercialize, promote, manufacture and distribute Horizant in the U.S.. XenoPort will not be responsible for any losses associated with the terminated collaboration agreement, and XenoPort will not receive any revenue or incur any losses from GSK's sales of Horizant during the transition period. GSK will also continue to fully fund the costs associated with the management and conduct of clinical studies initiated by GSK prior to the date of the termination and transition agreement. In addition, prior to the end of the transition period, GSK will provide to XenoPort inventory of gabapentin enacarbil in GSK's possession that is not required for use by GSK in the manufacture of Horizant. In exchange for such inventory, XenoPort will make annual payments to GSK of $1.0 mln for six years beginning in 2016.

[DAD2]

Glaxo out of the deal (almost):

http://www.nasdaq.com/article/glaxosmithkline-xenoport-end-horizant-collaboration-pact-20121108-00243#.UJugb-Q8CSo

[surf1944]

4:00PM Xenoport reports favorable metabolism and pharmacokinetics of XP23829, a novel fumaric acid ester, in Phase 1 trial (XNPT) 11.15 -0.15 : Co announced favorable preliminary results from a Phase 1 clinical trial in healthy adults designed to assess the pharmacokinetics, safety and tolerability of single doses of four different oral formulations of XP23829, a novel fumaric acid ester compound that is a prodrug of monomethyl fumarate. XP23829 is being developed for the potential treatment of relapsing-remitting multiple sclerosis and/or psoriasis. The trial demonstrated that administration of XP23829 resulted in the expected levels of MMF in the blood. As anticipated, the four formulations produced different PK profiles of MMF, including one formulation that could potentially be dosed two or three times a day and at least one formulation that may be suitable for once-a-day dosing. XP23829 was generally well-tolerated in the trial.